Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406015 · ClinicalTrials.gov registry record · NA
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT01406015 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 38 participants.
The verdict
NCT01406015, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.
Interventions
- DRUG Placebo
- DRUG Spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406015
The ClinicalTrials.gov registry entry for NCT01406015 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01406015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406015 about?
NCT01406015 is a clinical study titled "Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications". The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.
What is the current status of trial NCT01406015?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2009-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01406015?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG).
Who is sponsoring clinical trial NCT01406015?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.